EPAS1 and renal cell carcinoma: In recent developments, belzutifan, a pioneering inhibitor targeting HIF-2α, exhibited notable anti-tumor efficacy in individuals with VHL syndrome-related tumors, including renal cell carcinoma (RCC) [32].